Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF)'s (Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF)) John Lucas talks to Proactive London progress made across all four of the group's current drug development programmes.
He says both their lead assets are 'progressing smoothly through key clinical development'. With OCT461201, a cannabinoid-like compound for neuropathic and visceral pain, expected to enter phase 1 clinical trials in Q1 2023. And OCT130401, a combination of inhaled phytocannabinoids for Trigeminal Neuralgia, is expected to enter phase 1 clinical trials in Q4 2022.